SCHEMBL244905

SCHEMBL244905

Cc1ccc2c(-c3ccc(Cl)cc3)c([C@H](COC(=O)C(C)(C)C)OC(C)(C)C)c(C)cc2n1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.37
PSIP1 O75475 1/20 0.37
RAB9A P51151 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CYP3A4 P08684 1/20 0.36
POLB P06746 2/20 0.34
GRM2 Q14416 1/20 0.31
DHODH Q02127 4/20 0.31
CYP1A2 P05177 2/20 0.31
CYP2C9 P11712 2/20 0.31
CYP2C19 P33261 2/20 0.31
KDM4E B2RXH2 1/20 0.31
KMT2A Q03164 1/20 0.31
LTB4R Q15722 2/20 0.31
CRHR1 P34998 1/20 0.31
CYP2D6 P10635 1/20 0.30
HPGD P15428 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL244904 1.00 NPC1 (0.37) NPC1PSIP1RAB9ATDP1L3MBTL1
SCHEMBL244906 1.00 NPC1 (0.37) NPC1PSIP1RAB9ATDP1L3MBTL1
SCHEMBL245272 0.94 NPC1 (0.37) NPC1PSIP1RAB9ATDP1L3MBTL1
SCHEMBL245271 0.94 NPC1 (0.37) NPC1PSIP1RAB9ATDP1L3MBTL1
SCHEMBL245273 0.94 NPC1 (0.37) NPC1PSIP1RAB9ATDP1L3MBTL1
SCHEMBL245612 0.92 RAB9A (0.40) NPC1PSIP1RAB9ATDP1L3MBTL1
SCHEMBL245614 0.92 RAB9A (0.40) NPC1PSIP1RAB9ATDP1L3MBTL1
SCHEMBL245613 0.92 RAB9A (0.40) NPC1PSIP1RAB9ATDP1L3MBTL1
SCHEMBL245836 0.91 PSIP1 (0.36) NPC1PSIP1RAB9ATDP1L3MBTL1
SCHEMBL245838 0.91 PSIP1 (0.36) NPC1PSIP1RAB9ATDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588455-B1 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS GILEAD SCIENCES INC (US) 2018-04-04 EP disclosed
US-9296758-B2 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds GILEAD SCIENCES, INC. (US) 2016-03-29 US disclosed
US-20130210801-A1 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-08-15 US disclosed
EP-2588455-A1 2 -QUINOLINYL- ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS Gilead Sciences, Inc. (US) 2013-05-08 EP disclosed
WO-2012003498-A1 2 -QUINOLINYL- ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210801-A1 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS NFATC1, ACIN1, ARF1 NPC1 332/4885PSIP1 3417/4885RAB9A 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.